Form 4: Intellia Therapeutics Executive Laura Sepp-Lorenzino Reports Stock Transactions
SEC Form 4 Filing
Laura Sepp-Lorenzino, EVP and Chief Scientific Officer of Intellia Therapeutics, reports the acquisition of 3,500 shares of common stock and related restricted stock units.
Summary
- Laura Sepp-Lorenzino, EVP and Chief Scientific Officer of Intellia Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- The report indicates the acquisition of 3,500 shares of common stock on January 1, 2025, through the vesting of restricted stock units.
- Following the reported transaction, Sepp-Lorenzino beneficially owns 86,354 shares of Intellia Therapeutics common stock.
- The filing also includes a Limited Power of Attorney, granting James Basta and Edward Dulac the authority to execute SEC forms on Sepp-Lorenzino's behalf.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices and insider trading reporting, suggesting a neutral to slightly positive sentiment due to alignment of executive interests with shareholders.
Positives
- The acquisition of shares through RSU vesting aligns Sepp-Lorenzino's interests with those of the company and its shareholders.
- The reported transactions are part of a pre-existing compensation plan, indicating a structured approach to executive compensation.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. This filing indicates normal executive compensation and stock ownership adjustments.
Comparison to Industry Standards
- Executive compensation packages including RSUs are standard practice in the biotechnology industry, aligning executive incentives with shareholder value.
- Companies like CRISPR Therapeutics and Editas Medicine also utilize stock options and RSUs as part of their executive compensation plans.
- The vesting schedule of 25% annually is a common vesting structure for RSUs in the biotech sector.
Stakeholder Impact
- The reported stock transactions provide transparency to shareholders regarding executive stock ownership.
- The vesting of RSUs incentivizes the executive to contribute to the long-term success of the company, benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 2021-03-03 | Reporting person was granted 14,000 RSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. |
| 2024-06-30 | Includes 405 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan. |
| 2024-11-04 | Date of execution for the Limited Power of Attorney. |
| 2024-12-31 | Includes 556 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan. |
| 2025-01-01 | Transaction date for the acquisition of 3,500 shares of common stock through RSU conversion. |
| 2025-01-03 | Date of signature for the Form 4 filing. |
| 2031-03-02 | Expiration date of the Restricted Stock Units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.